Jude Onyia - 12 Feb 2026 Form 4 Insider Report for NEUROCRINE BIOSCIENCES INC (NBIX)

Role
Chief Scientific Officer
Signature
/s/ Darin Lippoldt, Attorney-in-Fact
Issuer symbol
NBIX
Transactions as of
12 Feb 2026
Net transactions value
-$1,872,633
Form type
4
Filing time
17 Feb 2026, 17:47:22 UTC
Previous filing
03 Feb 2026
Next filing
23 Feb 2026
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Onyia Jude Chief Scientific Officer 6027 EDGEWOOD BEND CT., SAN DIEGO /s/ Darin Lippoldt, Attorney-in-Fact 17 Feb 2026 0001894425

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction NBIX Common Stock Options Exercise $0 +2,560 +16% $0.000000 18,537 12 Feb 2026 Direct
transaction NBIX Common Stock Tax liability $175,541 -1,426 -7.7% $123.10 17,111 12 Feb 2026 Direct F1
transaction NBIX Common Stock Options Exercise $0 +2,690 +16% $0.000000 19,801 13 Feb 2026 Direct
transaction NBIX Common Stock Tax liability $180,222 -1,452 -7.3% $124.12 18,349 13 Feb 2026 Direct F1
transaction NBIX Common Stock Options Exercise $0 +2,717 +15% $0.000000 21,066 13 Feb 2026 Direct
transaction NBIX Common Stock Tax liability $181,960 -1,466 -7% $124.12 19,600 13 Feb 2026 Direct F1
transaction NBIX Common Stock Award $0 +19,935 +102% $0.000000 39,535 13 Feb 2026 Direct F2
transaction NBIX Common Stock Tax liability $1,334,911 -10,755 -27% $124.12 28,780 13 Feb 2026 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction NBIX Restricted Stock Unit Options Exercise $0 -2,560 -25% $0.000000 7,681 12 Feb 2026 Common Stock 2,560 Direct F3, F4
transaction NBIX Restricted Stock Unit Options Exercise $0 -2,690 -33% $0.000000 5,380 13 Feb 2026 Common Stock 2,690 Direct F3, F5
transaction NBIX Restricted Stock Unit Options Exercise $0 -2,717 -50% $0.000000 2,717 13 Feb 2026 Common Stock 2,717 Direct F3, F6
transaction NBIX Stock Option Award $0 +55,119 $0.000000 55,119 13 Feb 2026 Common Stock 55,119 $124.12 Direct F7
transaction NBIX Restricted Stock Unit Award $0 +9,669 $0.000000 9,669 13 Feb 2026 Common Stock 9,669 Direct F3, F8
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Shares withheld by Neurocrine Biosciences, Inc. (the "Company" or "Issuer") to satisfy tax withholding requirements on vesting of restricted stock units ("RSUs") or performance restricted stock units ("PRSUs"), as applicable. No shares were sold.
F2 On May 19, 2023, the Reporting Person was granted PRSUs representing the right to receive shares of the Issuer's common stock based upon the achievement of specified performance metrics over the three-year performance period ending on December 31, 2025. Effective February 13, 2026, the achievement of the applicable performance metrics and the resulting payout level were certified, and, as a result of such certification, the PRSUs vested at 125% of the target number of shares subject to the award.
F3 Each RSU represents a contingent right to receive one share of the Issuer's common stock.
F4 This RSU was granted to the Reporting Person on February 12, 2025. In accordance with the terms of the RSU, the award vested as to 2,560 shares on February 12, 2026, and will vest as to 2,560 shares on February 12, 2027, 2,560 shares on February 12, 2028, and 2,560 shares on February 12, 2029, subject to the terms and conditions of the award.
F5 This RSU was granted to the Reporting Person on February 13, 2024. In accordance with the terms of the RSU, the award vested as to 2,690 shares on February 13, 2025, vested as to 2,690 shares on February 13, 2026, and will vest as to 2,690 shares on February 13, 2027, and 2,690 shares on February 13, 2028, subject to the terms and conditions of the award.
F6 This RSU was granted to the Reporting Person on February 13, 2023. In accordance with the terms of the RSU, the award vested as to 2,717 shares on February 13, 2024, vested as to 2,717 shares on February 13, 2025, vested as to 2,717 shares on February 13, 2026, and will vest as to 2,717 shares on February 13, 2027, subject to the terms and conditions of the award.
F7 Represents option of which 1/48th of the shares underlying the option becomes vested and exercisable on March 13, 2026 and an additional 1/48th of the shares underlying the option becomes vested and exercisable each month thereafter.
F8 The Restricted Stock Units will vest annually at 1/4 of the units vesting on each of February 13, 2027, February 13, 2028, February 13, 2029, and February 13, 2030.